Fifty 410 vs. Trimi: prices, fine print, and the honest verdict

Tirzepatide pricing

Fifty 410 advertises tirzepatide from $133/mo but publishes no maintenance-dose figure, so it can't be ranked on the all-in basis — the honest label is “starting price only.” Trimi carries only a reported figure — $125/mo from a competing comparison site (May 2026), never captured on a provider page — so it is listed, reviewed, and excluded from ranked comparisons pending verification.

Transparency

Fifty 410: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. Trimi: Third-party-reported; dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Fifty 410: unknown; not published. Trimi: terms not published.

Two ladders, side by side

Titration is where these pricing structures stop being abstractions: Fifty 410 publishes only the $133 starting rung — the upper ladder is unpriced. A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The five normalizations, applied to this pair

1 · All-in, not advertised. Fifty 410 publishes no figure to normalize; Trimi's reported $125 can't be normalized because no source page confirms what it includes. 2 · Maintenance basis. Fifty 410 publishes only a starter figure ($133), which this normalization exists to catch. 4 · Evidence tiered. Fifty 410: source-verified, read 2026-08-05; Trimi: third-party-reported. 5 · Pharmacy weighed. Fifty 410 names no pharmacy; Trimi names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Fifty 410: no membership — the medication figure is the billed figure; not published; commitment: unknown. Trimi: no membership — the medication figure is the billed figure. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Fifty 410 carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Trimi carries third-party-reported pricing; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: Fifty 410: shipping unknown; consultation unknown. Trimi: shipping, consult, and refill logistics aren’t published in our capture — ask at intake, in writing. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Fifty 410 if its published terms happen to fit your state, format, or timing. Pick Trimi if its published terms happen to fit your state, format, or timing. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Fifty 410, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. For Trimi, ranking would require: a provider-page capture confirming the reported $125 figure and exactly what it includes; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

Widen the frame one step and the strongest adjacent options are NexLife at $215 (flat, no membership, named pharmacy); Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.